Ardelyx reports FY2023 revenue $124.5M; IBSRELA sales $80.1M, guides 2024 $140-150M

ARDELYX, INC.

2023-FY EPS reported -$0.30 revenue$124,456,000

IBSRELA net product sales $80.1M in FY2023, Q4 $28.1M (+26% QoQ); guides 2024 sales $140-150M.
XPHOZAH launch nets $2.5M in Q4 2023; initiated real-world study.
Total revenue $124.5M in 2023 (up 138% YoY from $52.2M); net loss $66.1M ($0.30 per share).
Cash and investments $184.3M at year-end, up from $123.9M; drew $22.4M from SLR term loan.
Kyowa Kirin launched PHOZEVEL (tenapanor) in Japan Feb 20, 2024; Ardelyx received $3M milestone from Fosun.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARDELYX, INC. updated its the fourth quarter of 2023 guidance (initiated).

Period: the fourth quarter of 2023
Guidance: initiated
Result: reported results

Exact text from the filing

During the fourth quarter of 2023, U.S. net product sales revenue was $28.1 million, reflecting 26% growth compared to the third quarter of 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARDELYX, INC. reported the year ended December 31, 2023 results: revenue Total revenues for the year ended December 31, 2023 were $124.5 million. Guidance initiated.

Period: the year ended December 31, 2023
Revenue: Total revenues for the year ended December 31, 2023 were $124.5 million
Guidance: initiated
Result: reported results

Exact text from the filing

Total revenues for the year ended December 31, 2023 were $124.5 million, compared to $52.2 million in total revenues in 2022, reflecting increased net product sales, licensing revenues and product supply revenue.

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-006321

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.